Importance of preabsorptive insulin release on oral glucose tolerance: studies in pancreatic islet transplanted rats

E G SIEGEL, E R TRIMBLE, A E RENOLD, AND H R BERTHOUD

From the Institut de Biochimie Clinique and Laboratoires de Recherches Médicales, University of Geneva, Geneva, Switzerland

SUMMARY The role of preabsorptive (cephalic phase) insulin release in oral glucose tolerance was investigated using diabetic rats treated by intraportal transplantation of isogenic islets. This early neurally mediated phase of insulin release has been shown to be absent in such rats. When the body weight of transplanted rats was normalised, glucose tolerance tests (GTTs) were performed in the unstressed state using permanent cardiac catheters. Transplanted rats had a normalised intravenous GTT, whereas, as we have shown previously, their oral GTT remained clearly pathological. During both tests peripheral insulin levels were decreased compared with controls. While during intravenous GTT the onset of insulin release occurred as early in transplanted rats as in controls, during oral GTT there was a clear delay, probably because of the absence of the cephalic phase. Re-establishment of normal preabsorptive insulin levels was attempted by a small intravenous insulin injection during this period. This resulted in a transient increase in peripheral insulin levels, which, at two minutes after glucose ingestion, gave values similar to those found in controls at that time. This small insulin injection caused a marked improvement of the oral GTT which was most evident after exogenous insulin had disappeared from the blood. While the injection did not affect the 60 minute incremental insulin area, the glucose area was decreased by 50%, to a value not significantly different from that of control rats. The cephalic phase of insulin release appears, therefore, to be one important factor in the control of glycaemia during food intake. Its absence plays a major role in the pathological oral glucose tolerance of diabetic rats treated by intraportal islet transplantation.

It has long been known that the disposal of orally ingested glucose is controlled not only by the increase in blood glucose concentration, but also by other factors such as gastrointestinal hormones and neural reflexes.1 Neural influences may be of particular importance when transplantation of pancreatic endocrine tissue is performed, as the transplant may remain denervated. We have shown, for example, that when a sufficient number of islets is transplanted to normalise the intravenous glucose tolerance in the unstressed rat, oral glucose tolerance in the same animals remains abnormal.2 Whereas after an intravenous glucose load plasma insulin levels rose as early in transplanted rats as in controls, after an oral glucose load transplanted rats displayed a delayed plasma insulin response. When tests designed to measure preabsorptive (cephalic phase) insulin release were performed, it was found that this part of the early insulin response was absent in islet-transplanted rats,3 as reported previously for diabetic rats treated by foetal pancreas transplants.4 It is known that the early insulin response after both intravenous5 6 and oral7 8 glucose loading is an important determinant of the overall glucose tolerance. Therefore, the present study was designed to define the importance of preabsorptive insulin release—or its absence—in maintaining normal oral glucose tolerance in previously diabetic rats treated by intraportal islet transplantation. To this end, islet transplanted rats had oral glucose tolerance tests performed with and without a small injection of insulin given intravenously during the preabsorptive period, in a dose calculated to mimic the levels seen during cephalic phase secretion. As stress affects glucose tolerance in islet transplanted
Importance of preabsorptive insulin release on oral glucose tolerance

Rats even more than in normal animals,

Care was taken to test animals in the conscious unstressed state.

Methods

Animals

Highly inbred male Wistar-Lewis rats obtained from the Charles-River Breeding Laboratories, Wilmington, Mass., were used. After food had been withdrawn for 12 to 16 hours, diabetes was induced in rats weighing 200–250 g (8–10 weeks old) by the intravenous injection of streptozotocin (50 mg/kg) freshly dissolved in acidified saline (pH 4.5). Control rats received an intravenous injection of acidified saline. Islet transplantation or sham operation was performed four to five weeks later. Islets were isolated by a modification of the collagenase technique.

After hand-picking, the islets were suspended in modified Krebs-Ringer bicarbonate (KRB) buffer containing Na⁺ 145.6, K⁺ 6.0, Ca²⁺ 2.0, Mg²⁺ 2.4, Cl⁻ 127.8, PO₄³⁻ 1.2, SO₄²⁻ 2.4, HCO₃⁻ 24.6 mEq/l, 5.5 mM glucose, and 1% bovine serum albumin. An aliquot was taken from each batch of islets for measurement of insulin content. A known number of islets was then placed in a silicnicised glass syringe containing 0.2–0.3 ml KRB buffer. The recipient rat was anaesthetised with sodium pentobarbital. The abdomen was opened through a midline incision and the portal vein exposed. A 23-gauge needle, connected by a fine catheter to the syringe, was inserted into the portal vein and the islets were slowly injected. After the injection, the syringe, catheter, and needle were repeatedly flushed into a Petri dish and the remaining islets were counted.

Glucose Tolerance Tests

Thirteen to 15 weeks after transplantation or sham operation of non-diabetic control rats, permanent cardiac catheters were implanted via the jugular vein according to the method of Steffens. These catheters were filled with a 60–70% polyvinylpyrrolidone (PVP) solution containing heparin 500 U/ml and penicillin 20 000 U/ml; the mixture was aspirated every second day and the whole catheter was flushed out with heparinised saline and then refilled with the PVP/heparin/saline solution. By this means catheters could be used for six to eight weeks. Animals were housed individually in special cages, handled frequently, and all tests were carried out in their home cages. The tests were started one to two weeks after catheter implantation when the rats had returned to a normal rate of weight gain.

The rats were habituated to the blood-sampling procedure and to drinking a glucose solution when it was presented. Tests were performed in the afternoon, six to eight hours after food withdrawal. Before the test, an extension tube was attached to the cardiac catheter, 50–100 U heparin was given per rat, and 20 to 30 minutes later the tests were begun. After two basal blood samples glucose was injected via the cardiac catheter or presented in a petri dish for oral consumption. Zero time for the oral test was when the rat spontaneously began to drink the glucose solution, and for the intravenous test when glucose was injected. After intravenous glucose loading, the catheter was flushed through several times with saline to remove any traces of glucose. The glucose loads and blood-sampling times for each test are as follows:

**IVGTT** Glucose load 1 g/kg (40% glucose solution).

Sampling times: basal (twice), 2, 5, 10, 20, 40, and 60 minutes.

**OGTT** Glucose load 1g/kg and 2g/kg (40% glucose solution). Sampling times: basal (twice), 2, 5, 10, 20, 40, 60, 90, and 120 minutes.

**ORAL GTT** (1g/kg) with insulin injection

The procedure was similar to the above except that an intravenous injection of Actrapid insulin (Novo) was given during the first minute (55–60 s) after the rat had started to take the glucose. The dose of insulin was calculated to mimic the concentration found in peripheral veins during cephalic phase release. These calculations were made taking into account the known disappearance rate of intravenously injected insulin in rats and adjusted empirically after pilot experiments in normal rats under basal conditions. Each blood sample was 200 μl. The total blood withdrawn was therefore small (1–6–2 ml) and it was replaced at the end of each test. The time interval between tests was three to five days.

Pancreas and Islet Extraction for Determination of Insulin Content

Immediately after death the pancreata were removed, weighed, and stored at −20°C. Insulin was extracted by a modification of the Kenny technique, using acidified ethanol (0.7 M HCl/ethanol, 1:3 v/v). Acidified ethanol was also used for the extraction of islet insulin from the isolated islets.

Assays

Plasma and urinary glucose concentrations were measured by a glucose oxidase method. Immuno-reactive insulin was measured according to Herbert et al. using rat insulin standard and guinea-pig antipork insulin serum.
MATERIALS
Streptozotocin was a gift from Dr W J Dulin, Upjohn Company, Kalamazoo, Michigan. Collagenase (type IV) was obtained from Serva GmbH, Heidelberg, West Germany. Rat insulin standard was obtained from Dr J Schlichtkrull, Novo Research Institute, Bagsvaer, Denmark. Guinea-pig anti-insulin serum was a gift from Dr H H Schone, Farbwerke Hoechst, Frankfurt, West Germany. Insulin Actrapid was obtained from Novo Industri, Copenhagen, Denmark.

PRESENTATION OF RESULTS AND STATISTICAL METHODS
Results are given as mean ± SEM unless stated otherwise. The glucose and insulin areas for the various glucose tolerance tests were calculated by integrating the incremental glucose and insulin concentrations above basal for each animal. Student's two-tailed unpaired t test was used to evaluate differences between transplanted rats and controls. Student's two-tailed paired t test was used to assess differences between the oral GTTs with and without injected insulin in the same animal.

Results

TRANSPLANTED ISLETS
The number of islets injected per animal was 2106 ± 266. The mean insulin content of these islets was 27.9 ± 2.1 ng/islet so that the total insulin content of the islets transplanted to each rat was approximately 59 μg. The mean pancreatic insulin content for the rat strain at this age was found to be 96 ± 10 μg/pancreas (n=5) so that the amount of insulin contained in the transplanted islets corresponded to about 62% of the content of one normal rat pancreas.

DEVELOPMENT OF BODY WEIGHT
The body weight of transplanted rats and of diabetic and non-diabetic controls is shown in Fig. 1. Animals injected with streptozotocin stopped gaining weight. They, in fact, lost about 10 g over the period of investigation. Not all diabetic controls survived for the whole period, however, so that the value shown for six surviving animals corresponds to a positive selection. After four weeks of diabetes (zero time, Fig. 1) the mean weight of the recipient rats was about 75 g less than that of the age-matched non-diabetic controls at the time of transplantation. Rapid weight gain occurred after transplantation, so that from the eighth week onwards no significant difference was observed between transplanted rats and non-diabetic controls. Transplanted rats gained 223 ± 21 g and non-diabetic controls 164 ± 14 (p<0.05) during the 14 weeks after transplantation.

METABOLIC STATE OF DIABETIC RATS BEFORE AND AFTER TRANSPLANTATION
The urine volume of diabetic rats before transplantation was 148 ± 13 ml/24 h and the glucose excretion 12.7 ± 1.7 g/24 h. After transplantation the urine volume decreased rapidly, reaching 10 ± 2 ml/24 h in the second week, a volume no longer significantly different from non-diabetic controls (6 ± 2 ml/24 h, range 4–12 ml). Urine volumes remained stable after the third week. Urine was free from glucose as measured by Testape (Lilly), from the second week onwards. The mean plasma glucose in rats before transplantation was 37.1 ± 2.4 mmol/l.

---

Fig. 1 Development of body weight in rats after islet transplantation. Rats were transplanted or sham-operated four to five weeks after streptozotocin injection (50 mg/kg). Permanent venous catheters for use in glucose tolerance tests were implanted 13 to 15 weeks after transplantation.
Importance of preabsorptive insulin release on oral glucose tolerance

Fig. 2 Plasma glucose and insulin concentrations in conscious unstressed rats during intravenous GTT (1 g/kg). The curves compare islet-transplanted rats to non-diabetic controls 14 to 16 weeks after transplantation. Glucose was administered at 0 min, the early time points were two, five, and 10 minutes, ns = P > 0.05, 1 ng insulin = 24 μU.

Table Incremental insulin and glucose areas

<table>
<thead>
<tr>
<th>Transplants</th>
<th>p</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incremental areas during IVGTT (60 min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose areas</td>
<td>423 ± 73</td>
<td>&gt;0.10</td>
</tr>
<tr>
<td>Insulin areas</td>
<td>121 ± 19</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Incremental glucose areas during oral GTT (60 min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without insulin injection</td>
<td>307 ± 63</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>With insulin injection</td>
<td>155 ± 45</td>
<td>&gt;0.10</td>
</tr>
<tr>
<td>Incremental insulin areas during oral GTT (60 min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without insulin injection</td>
<td>128 ± 20</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>With insulin injection</td>
<td>131 ± 28</td>
<td>&gt;0.10</td>
</tr>
<tr>
<td>Incremental insulin areas during first 5 min of oral GTT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without insulin injection</td>
<td>26 ± 1.2</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>With insulin injection</td>
<td>14.2 ± 1.9</td>
<td>&gt;0.10</td>
</tr>
</tbody>
</table>

The areas were calculated by integrating the insulin or glucose values above basal for each individual rat. Statistical comparison was by Student's unpaired t test when transplanted rats were compared with controls and by the paired, when the rats with insulin injection were compared with themselves without insulin injection. Values are mean ± SEM, n = 5, for both transplanted rats and controls.

(n = 5) and was normalised by transplantation (see below). Non-diabetic controls had plasma glucose values of 6.9 ± 0.6 mmol/l (n = 5) before sham operation. At death the insulin content of the pancreas in transplanted rats was 0.50 ± 0.05% of non-diabetic controls and that of diabetic controls was 0.46 ± 0.22%.

Glucose tolerance tests

Permanent cardiac catheters for use in glucose tolerance tests were implanted after the weight of the transplanted rats had caught up with that of the age-matched controls (13th to 15th week, Fig. 1). Tests were started one week after this operation when the rats had regained their preoperative weight. The mean basal plasma glucose values for all the tests described below (calculated from the mean of six values for each animal) were 6.8 ± 0.2 for five non-diabetic controls, and 6.8 ± 0.1 mmol/l for five transplanted rats. The mean basal plasma

Fig. 3 Plasma glucose and insulin concentrations in conscious unstressed rats during oral GTT (1 g/kg). The curves compare the oral glucose tolerance of the same animals as Fig. 2. Tests were started (0 min) when the rat spontaneously began to take the glucose. Early blood sampling was at two, five and 10 minutes. The insert shows the first 5 min of the insulin curves on an expanded scale, 1 ng insulin = 24 μU.
planted and control rats both showed a rapid insulin response with maximal insulin concentrations achieved at two minutes. The insulin concentrations, however, were significantly lower in transplanted rats during the first 20 minutes, and the incremental insulin areas were smaller in transplanted rats than in controls (Table). No significant difference was seen in the incremental glucose areas.

**ORAL GTT (1 g/kg, 2 g/kg)**

In contrast with the plasma glucose values reached after intravenous glucose, during oral GTT after 20 minutes consistently higher plasma glucose levels were observed in transplanted rats than in controls (Fig. 3). Mean values of plasma glucose above 11 mmol/l were found at 20 and 40 minutes. The integrated incremental glucose area was also significantly greater in transplanted rats than in controls (Table).

As early as two minutes after the start of the oral glucose ingestion, before a significant rise in plasma glucose could be observed, non-diabetic controls

**INTRAVENTOUS GTT (1 g/kg)**

During the intravenous glucose tolerance test the glucose values of transplanted rats were not significantly different from controls (Fig. 2), although they showed a tendency to have slightly higher values at some time points. The mean K-value for transplanted rats (2.41 ± 0.17) was similar to that of non-diabetic controls (2.53 ± 0.08, p > 0.40). Trans-
importance of preabsorptive insulin release on oral glucose tolerance

exhibited a significant increase of plasma insulin above their own basal level (mean increase 2.5 ± 0.6 mg/ml, p < 0.02), whereas transplanted rats showed no such rise in plasma insulin at the same two minute time point (mean increase 0.2 ± 0.3 ng/ml). The incremental 60 minute insulin area for transplanted rats was about 50% that of controls (Table). An oral GTT using a larger dose (2 g/kg) was performed only in three transplanted rats. The 60 minute incremental insulin area was 62% greater (p < 0.05) than that during the test with 1 g/kg in the same rats. Therefore, islet-transplanted rats had not reached the limit of their insulin secretory capacity during the 1 g/kg oral GTT. While overall insulin release in transplanted rats was reduced during oral GTT compared with that of controls, there was a disproportionate decrease during the early part of the test (see Table), no rise in plasma insulin being observed during the preabsorptive period.

oral GTT (1 g/kg) with intravenous insulin injection

To investigate whether the absence of preabsorptive insulin response influenced subsequent glucose tolerance in transplanted rats, a small dose of insulin was given intravenously through the indwelling catheter. The dose injected was 24 mU/kg Actrapid, given exactly one minute after the rat had spontaneously started to drink the glucose solution. In transplanted rats this resulted in an increase of the plasma insulin concentration of 3.6 ± 1.4 ng/ml at two minutes compared with the level measured in the test without insulin injection in the same rats (Fig. 4). No effect of the insulin injection on plasma insulin levels was detectable at five minutes nor at any later time point.

The small and transitory plasma insulin increase was associated with a striking overall amelioration of the oral glucose tolerance profile. The decrease of plasma glucose induced by the insulin injection was significant at 10 and 20 minutes. Furthermore, although every individual rat exhibited lower values also at 40, 60, and 90 minutes this did not reach statistical significance (0.05 < p < 0.10 for all points) because the decrease achieved varied. The improvement in glucose tolerance was also evident from the highly significant decrease in the incremental glucose area induced by the insulin injection (Table).

Although non-diabetic controls have preabsorptive insulin release, intravenous insulin injections at one minute were also carried out in that group (Fig. 5). This resulted in an increase in plasma insulin of 3.2 ± 1.3 ng/ml at two minutes above that found in the test without injection. Apart from this increase, the only detectable effect on plasma insulin levels was a decrease at 10 minutes compared with the tolerance test without insulin injection. This coincided with a small, but significant, decrease of plasma glucose at the same time (10 minutes).

Results can be summarised by describing the changes in incremental glucose and insulin areas (Table). In transplanted rats without insulin injection during the preabsorptive period the glucose areas were increased and insulin areas were decreased compared with controls. The insulin injection given in the preabsorptive period increased the five minute insulin area to a value comparable with that found in controls without insulin injection, whereas the 60 minute incremental insulin area was unchanged. By contrast, the insulin injection markedly reduced the incremental glucose area to a value which, although still retaining some tendency to be greater than, was not significantly different from that of controls.

Discussion

This study clearly demonstrates that, in transplanted rats, known to have absent cephalic phase insulin secretion,2 an intravenous injection of insulin which mimicked this early phase of insulin release, both with respect to its timing and to its magnitude, exerted a remarkable effect on oral glucose tolerance. It is striking that, in transplanted rats, although plasma insulin levels at five minutes and later were not affected by the small dose of exogenous insulin, a marked improvement in glucose levels was achieved over the whole observation period of the glucose tolerance test. When the effect of the intravenous insulin injection at one minute is described in terms of integrated insulin and glucose areas the effect of injection in enlarging the insulin area was limited to the first five minutes, whereas the incremental insulin area over 60 minutes in transplanted rats was not affected. The 60 minute glucose area in transplanted rats was, however, reduced by half, while the insulin injection had no effect on the glucose area in controls which have intact cephalic phase insulin release. Even in controls, the transient increase in plasma insulin levels at two minutes, superimposed on an intact cephalic phase, exerted a small but significant effect on plasma glucose and on plasma insulin levels seen only at 10 minutes—that is, after exogenous insulin had disappeared from the blood. Therefore, even normal rats with an intact cephalic phase appear to be sensitive to small alterations in plasma insulin in the preabsorptive period.

Overall insulin output, as measured as insulin levels in peripheral blood, was less in transplanted
rats than in controls during both oral and intravenous glucose tolerance. Caution should, however, be taken in extrapolating from peripheral plasma insulin levels to the amount secreted. In normal rats, 50% of secreted insulin can be extracted during one passage through the liver, whereas no such data exist for rats with islets transplanted to the liver where regions of low and high insulin concentrations are found within the organ. The insulin areas of controls during an oral GTT were comparable with those during an intravenous GTT (Table). The insulin areas of transplanted rats were reduced by a similar amount during both tests. For the intravenous GTT, the insulin output was sufficient to normalise the K-values, whereas the oral GTT remained clearly abnormal. While during the intravenous GTT the onset of insulin release occurred as early in transplanted rats as in controls, during the oral GTT transplanted rats showed a clear delay in their insulin response.

The lack of early insulin response during oral GTT can be attributed, at least in part, to a missing cephalic phase of insulin release. This phase of insulin release occurs before the absorption of nutrients, via efferent fibres of the vagus nerve. Physiological importance of cephalic phase insulin secretion in oral glucose tolerance has been shown in experiments where the reflex has been by-passed in otherwise intact rats with permanent gastric catheters. Fifteen and 20 minutes after intragastric administration of glucose, plasma glucose levels were higher and plasma insulin levels were lower than when the same load was given orally. Higher plasma glucose concentrations were also found after intragastric administration of a mixed meal. After abolition of the reflex by vagotomy otherwise intact rats showed much higher plasma glucose levels during an oral glucose tolerance test than did normal controls. Cephalic phase insulin release can be abolished in dogs by chemical vagotomization— that is, atropinisation. In man atropinisation has been shown to cause deterioration of oral glucose tolerance while intravenous glucose tolerance remained intact. It is not surprising, therefore, that islet-transplanted rats, with presumably vagotomised β-cells and no cephalic phase insulin release, should exhibit abnormal oral glucose tolerance, even when intravenous glucose tolerance has been normalised. Whether, in addition, gastrointestinal hormones such as gastric inhibitory polypeptide hormones such as gastric inhibitory polypeptide and gastrin, which play a role in the insulin response to oral glucose, may have contributed to this phenomenon remains to be established. It seems unlikely, however, that their secretion would be abnormal in transplanted rats with intact innervation of the gastrointestinal tract and normalised body weight.

While decreased insulin secretory capacity not related to cephalic phase may have contributed to the pathological 1 g/kg oral GTT in islet-transplanted rats, results from the 2 g/kg test demonstrate that the transplanted rats had not reached the limit of their insulin secretory capacity during the 1 g/kg test. The principal observation reported here is that an artificially reestablished ‘cephalic phase insulin response’ resulted in remarkably improved oral glucose tolerance most clearly seen some time after exogenous insulin has disappeared from the blood. A preabsorptive increase of 2.5 ng/ml in peripheral plasma insulin in controls two minutes after oral glucose may seem rather small. However, the increase in portal vein insulin concentrations at that time is almost certainly much greater, a finding that has been demonstrated in dogs during the first five minutes of an oral GTT. In man, portal insulin levels are twice as high as in the periphery in the basal state and may be as much as 10 times greater when insulin release is stimulated. In addition, it has been shown that the disappearance rate of intraportally injected insulin is greater than that of insulin injected into the periphery. Therefore, an insulin injection calculated to mimic peripheral insulin levels at two minutes probably does not overestimate the amount of insulin actually secreted from the pancreas during the preabsorptive phase. In addition, insulin secreted into the portal circulation is more effective in improving the metabolic state of pancreas-transplanted rats than is insulin secreted into the periphery. Nevertheless, the peripheral injection of a small amount of insulin caused striking changes in overall oral glucose tolerance of islet-transplanted rats. This result suggests an important physiological role for the neurally-mediated cephalic phase insulin response.

After intravenous glucose administration, the liver accounts for about 10% of the glucose metabolised as opposed to 60% after oral administration of glucose. In general, the function of cephalic phase responses is to prepare the gastrointestinal tract to digest and absorb food and to prepare the viscera to metabolise and store nutrients. The primary physiological role of cephalic phase insulin secretion may thus be to prime the liver for the uptake of glucose absorbed from the intestines. Pathological oral glucose tolerance may, therefore, occur when cephalic phase insulin secretion is absent and the liver is not prepared for this task.
Importance of preabsorptive insulin release on oral glucose tolerance

The authors are grateful to Mrs Liza Caviller, Mrs Danielle Nappey, and Miss Dominique Rutschmann for their excellent technical help. This work was supported by grant nos. 3.774.0.76, 3.154.0.77, 3.487.0.79 of the Swiss National Science Foundation and NIH grant no. RO1 AM 25220-01.

References

5Brunzell JD, Robertson RP, Lerner RL et al. Relationship between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222–9.
22Powley TL. The ventromedial hypothalamic syndrome, satiety, and a cephalic phase hypothesis. Psychol Rev 1977; 84: 89–126.
Importance of preabsorptive insulin release on oral glucose tolerance: studies in pancreatic islet transplanted rats
E G Siegel, E R Trimble, A E Renold and H R Berthoud

Gut 1980 21: 1002-1009
doi: 10.1136/gut.21.11.1002